Pacira Pharmaceuticals Inc (NASDAQ:PCRX) has been given a consensus rating of “Hold” by the twenty-one brokerages that are covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating on the company. The average 12 month target price among analysts that have covered the stock in the last year is $55.13.
A number of equities analysts have weighed in on the company. Zacks Investment Research downgraded Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 3rd. Needham & Company LLC set a $60.00 price objective on Pacira Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, November 1st. ValuEngine downgraded Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 2nd. Piper Jaffray Companies set a $55.00 price target on Pacira Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, November 1st. Finally, HC Wainwright upped their target price on Pacira Pharmaceuticals to $60.00 and gave the stock a “buy” rating in a research note on Friday, November 2nd.
Shares of PCRX stock traded up $0.19 during trading hours on Friday, reaching $38.36. The stock had a trading volume of 344,700 shares, compared to its average volume of 796,475. The stock has a market cap of $1.57 billion, a PE ratio of -66.14 and a beta of 1.57. The company has a quick ratio of 7.83, a current ratio of 8.66 and a debt-to-equity ratio of 0.95. Pacira Pharmaceuticals has a twelve month low of $26.95 and a twelve month high of $55.00.
In other news, Director Andreas Wicki sold 14,527 shares of Pacira Pharmaceuticals stock in a transaction dated Thursday, December 13th. The stock was sold at an average price of $46.84, for a total transaction of $680,444.68. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Gary W. Pace acquired 4,500 shares of the business’s stock in a transaction that occurred on Monday, November 19th. The stock was bought at an average cost of $46.18 per share, for a total transaction of $207,810.00. Following the completion of the purchase, the director now owns 32,819 shares of the company’s stock, valued at $1,515,581.42. The disclosure for this purchase can be found here. Insiders have sold 164,748 shares of company stock worth $8,032,891 in the last ninety days. 5.90% of the stock is currently owned by insiders.
Hedge funds have recently bought and sold shares of the business. Bouchey Financial Group Ltd purchased a new position in shares of Pacira Pharmaceuticals during the 3rd quarter valued at $221,000. Boston Private Wealth LLC purchased a new stake in Pacira Pharmaceuticals in the 3rd quarter worth approximately $246,000. First Republic Investment Management Inc. bought a new position in shares of Pacira Pharmaceuticals in the 3rd quarter worth approximately $258,000. Parametrica Management Ltd bought a new position in Pacira Pharmaceuticals during the 3rd quarter valued at approximately $259,000. Finally, Baird Financial Group Inc. bought a new stake in shares of Pacira Pharmaceuticals in the 3rd quarter worth $288,000. 97.84% of the stock is currently owned by institutional investors and hedge funds.
About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.
Recommended Story: Why is the LIBOR significant?
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.